Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

• Status: Completed
• Trial end date: 2018-11-01

Summary

This is a Phase 1 dose-escalation study with three dose levels to determine the maximum tolerated dose of REOLYSIN® combined with FOLFIRI and bevacizumab.

• Phase: Phase 1

Details

• Lead Sponsor: Oncolytics Biotech
• Collaborator: Montefiore Medical Center
• Treatments: Bevacizumab; Fluorouracil; Irinotecan; Leucovorin